{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:19:30Z","timestamp":1788283170089,"version":"build-2803163510"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jocn.2026.111977","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:18:20Z","timestamp":1772857100000},"page":"111977","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study"],"prefix":"10.1016","volume":"148","author":[{"given":"Dimitrios K.","family":"Kitsos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantina","family":"Stavrogianni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios","family":"Giannopapas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia-Makrina","family":"Dimitriadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Akrivaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios K.","family":"Chasiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fotios","family":"Roussos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tagaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios C.","family":"Mastorodemos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Tzartos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Tsivgoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Giannopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0005","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple Sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jocn.2026.111977_b0010","first-page":"399","article-title":"Multiple Sclerosis and Pregnancy: Maternal Considerations","volume":"8","author":"Alwan","year":"2012","journal-title":"Women\u2019s Health"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0015","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/13524585231223395","article-title":"Use of multiple sclerosis disease-modifying therapies during pregnancy in France: Nationwide study between 2010 and 2021","volume":"30","author":"Swital","year":"2024","journal-title":"Mult Scler J"},{"key":"10.1016\/j.jocn.2026.111977_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106643","article-title":"Pregnancy and Multiple Sclerosis: a Narrative Review of Clinical Outcomes, disease activity, and Treatment Considerations","volume":"102","author":"Wyszynski","year":"2025","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.jocn.2026.111977_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11940-021-00666-4","article-title":"Treatment of Women with Multiple Sclerosis Planning Pregnancy","volume":"23","author":"Krysko","year":"2021","journal-title":"Curr Treat Options Neurol"},{"issue":"24","key":"10.1016\/j.jocn.2026.111977_b0030","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000012084","article-title":"Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women with Multiple Sclerosis","volume":"96","author":"Yeh","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2026.111977_b0035","first-page":"1","article-title":"First-Line use of Higher-Efficacy Disease-Modifying Therapies in Multiple Sclerosis","author":"Freedman","year":"2025","journal-title":"Canadian Consensus Recommendations Canadian Journal of Neurological Sciences \/ Journal Canadien des Sciences Neurologiques"},{"issue":"13","key":"10.1016\/j.jocn.2026.111977_b0040","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1007\/s40265-013-0102-7","article-title":"Natalizumab: a Review of its use in the Management of Relapsing-Remitting Multiple Sclerosis","volume":"73","author":"McCormack","year":"2013","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.jocn.2026.111977_b0045","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.msard.2014.08.005","article-title":"Natalizumab reduces relapse clinical severity and improves relapse recovery in MS","volume":"3","author":"Lublin","year":"2014","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.jocn.2026.111977_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.103995","article-title":"Use of natalizumab in persons with multiple sclerosis: 2022 update","volume":"65","author":"Morrow","year":"2022","journal-title":"Mult Scler Relat Disord"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0055","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200253","article-title":"Practical Considerations for Managing Pregnancy in patients with Multiple Sclerosis","volume":"14","author":"Graham","year":"2024","journal-title":"Neurol Clin Pract"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0060","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/13524585211052168","article-title":"Natalizumab concentrations during pregnancy in three patients with multiple sclerosis","volume":"28","author":"Toorop","year":"2022","journal-title":"Mult Scler J"},{"issue":"10","key":"10.1016\/j.jocn.2026.111977_b0065","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab","volume":"90","author":"Portaccio","year":"2018","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/practneurol-2018-002060","article-title":"UK consensus on pregnancy in multiple sclerosis: \u2018Association of British Neurologists\u2019 guidelines","volume":"19","author":"Dobson","year":"2019","journal-title":"Pract Neurol"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1177\/1352458517751049","article-title":"ECTRIMS\/EAN Guideline on the pharmacological treatment of people with multiple sclerosis","volume":"24","author":"Montalban","year":"2018","journal-title":"Mult Scler J"},{"issue":"7","key":"10.1016\/j.jocn.2026.111977_b0080","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1177\/1352458514554056","article-title":"Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis","volume":"21","author":"Vukusic","year":"2015","journal-title":"Mult Scler J"},{"issue":"7","key":"10.1016\/j.jocn.2026.111977_b0085","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab Use during the Third Trimester of Pregnancy","volume":"71","author":"Haghikia","year":"2014","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.jocn.2026.111977_b0090","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1136\/jnnp-2023-332804","article-title":"Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy","volume":"95","author":"Thiel","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.jocn.2026.111977_b0095","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3390\/ctn8030026","article-title":"Recommendations for the Treatment of Multiple Sclerosis in Family Planning, Pregnancy and Lactation in Switzerland: Immunotherapy","volume":"8","author":"Graber","year":"2024","journal-title":"Clinical and Translational Neuroscience"},{"issue":"1","key":"10.1016\/j.jocn.2026.111977_b0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the Tysabri\u00ae (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend","year":"2016","journal-title":"BMC Neurol"},{"key":"10.1016\/j.jocn.2026.111977_b0105","doi-asserted-by":"crossref","unstructured":"Landi D, Bovis F, Grimaldi A, et al. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. Published online September 30, 2022:jnnp-2022-329657. doi: 10.1136\/jnnp-2022-329657.","DOI":"10.1136\/jnnp-2022-329657"},{"issue":"5","key":"10.1016\/j.jocn.2026.111977_b0110","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1177\/1352458520912637","article-title":"Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis","volume":"27","author":"Demortiere","year":"2021","journal-title":"Mult Scler J"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0115","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2026.111977_b0120","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/MRR.0000000000000057","article-title":"Validity and reliability of the Greek version of the Modified Fatigue Impact Scale in multiple sclerosis patients","volume":"37","author":"Bakalidou","year":"2014","journal-title":"Int J Rehabil Res"},{"key":"10.1016\/j.jocn.2026.111977_b0125","doi-asserted-by":"crossref","unstructured":"World Medical Association Declaration of Helsinki. JAMA. 2013;310(20):2191. doi:10.1001\/jama.2013.281053.","DOI":"10.1001\/jama.2013.281053"},{"key":"10.1016\/j.jocn.2026.111977_b0130","unstructured":"Editor\/add author: De Onis Mercedes. WHO Child Growth Standards - Length\/Height-for-Age, Weight-for-Age, Weight-for-Length, Weight-for-Height and Body Mass Index-for Age\u00a0: Methods and Development. World Health Organization; 2006."},{"key":"10.1016\/j.jocn.2026.111977_b0135","unstructured":"WHO Child Growth Standards\u00a0: Head Circumference-for-Age, Arm Circumference-for-Age, Triceps Skinfold-for-Age and Subscapular Skinfold-for-Age\u00a0: Methods and Development. World Health Organization, Department of Nutrition for Health and Development; 2007."},{"key":"10.1016\/j.jocn.2026.111977_b0140","unstructured":"IBM Corp. IBM SPSS Statistics for Windows. IBM Corp. Preprint posted online October 18, 2024:30.0.0.0."},{"key":"10.1016\/j.jocn.2026.111977_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105557","article-title":"Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies","volume":"85","author":"Sahloul","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"10.1016\/j.jocn.2026.111977_b0150","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3390\/ph16050770","article-title":"Monoclonal Antibodies in Pregnancy and Breastfeeding in patients with Multiple Sclerosis: a Review and an Updated Clinical Guide","volume":"16","author":"Gklinos","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0155","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/bdrb.20189","article-title":"Effects of natalizumab, an \u03b14 integrin inhibitor, on the development of Hartley guinea pigs","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0160","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/bdrb.20190","article-title":"Embryo\/fetal development in cynomolgus monkeys exposed to natalizumab, an \u03b14 integrin inhibitor","volume":"86","author":"Wehner","year":"2009","journal-title":"Birth Defects Res B"},{"issue":"8","key":"10.1016\/j.jocn.2026.111977_b0165","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1177\/1352458511401944","article-title":"Pregnancy and natalizumab: results of an observational study in 35 accidental pregnancies during natalizumab treatment","volume":"17","author":"Hellwig","year":"2011","journal-title":"Mult Scler J"},{"issue":"5","key":"10.1016\/j.jocn.2026.111977_b0170","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1097\/GCO.0000000000000731","article-title":"Pregnancy and multiple sclerosis: an update","volume":"33","author":"Varyt\u0117","year":"2021","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.jocn.2026.111977_b0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1111\/j.1600-0404.2010.01426.x","article-title":"Delivery of healthy babies after natalizumab use for multiple sclerosis: a report of two cases","volume":"123","author":"Hoevenaren","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"10.1016\/j.jocn.2026.111977_b0180","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1007\/s42399-025-01878-4","article-title":"Disease Progression in Pregnant Women with Relapsing\u2013Remitting Multiple Sclerosis Treated with Fingolimod or Natalizumab prior to Conception: a Systematic Review","volume":"7","author":"Meneses","year":"2025","journal-title":"SN Compr Clin Med"},{"issue":"2","key":"10.1016\/j.jocn.2026.111977_b0185","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1136\/jnnp-2023-331525","article-title":"Early postpartum treatment strategies and early postpartum relapses in women with active multiple sclerosis","volume":"95","author":"Haben","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jocn.2026.111977_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105738","article-title":"Patterns of disease-modifying therapy utilization before, during, and after pregnancy and postpartum relapses in women with multiple sclerosis","volume":"88","author":"Bove","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"sup6","key":"10.1016\/j.jocn.2026.111977_b0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2217\/nmt.15.61","article-title":"Multiple Sclerosis and Family Planning","volume":"5","author":"Hellwig","year":"2015","journal-title":"Neurodegener Dis Manag"},{"issue":"1","key":"10.1016\/j.jocn.2026.111977_b0200","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/ene.15559","article-title":"Pregnancy outcomes after early fetal exposure to injectable first\u2010line treatments, dimethyl fumarate, or natalizumab in danish women with multiple sclerosis","volume":"30","author":"Andersen","year":"2023","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2026.111977_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104087","article-title":"Fetal and post-natal growth in infants of mothers with multiple sclerosis: a case-control stud","volume":"65","author":"Marozio","year":"2022","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826001281?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826001281?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:24:14Z","timestamp":1782408254000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826001281"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"alternative-id":["S0967586826001281"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111977","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal and neonatal outcomes following natalizumab use during pregnancy in women with multiple sclerosis: A multicenter observational study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.111977","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"111977"}}